News

January 6, 2022

Enteris BioPharma Highlights 2021 Achievements and 2022 Outlook

Enteris continues to capitalize on multiple value building opportunities involving Peptelligence® and ProPerma® platforms Received two milestone payments totaling $15 million from Cara Therapeutics per license […]
December 20, 2021

Enteris BioPharma to Participate in Biotech Showcase Virtual and BIO Partnering at JPM During “J.P. Morgan Week 2022”

Boonton, NJ, December 20, 2021  — Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of […]
December 9, 2021

SWK Holdings’ Subsidiary, Enteris BioPharma, Receives $5 Million Milestone Payment from Cara Therapeutics

Fourth milestone payment triggered by successful completion of process technology transfer related to the development of Oral KORSUVA™ Dallas, TX, December 09, 2021  — SWK Holdings Corporation […]
November 2, 2021

Enteris BioPharma Publishes White Paper on Best Practices in the Manufacturing of HPAPI Solid Oral Drug Products

Paper Examines the Opportunities and Challenges in Working with High Potency APIs Boonton, NJ, November 02, 2021  — Enteris BioPharma, Inc., a biotechnology company developing innovative drug […]
October 26, 2021

Enteris BioPharma
to Participate in the Partnership Opportunities in Drug Delivery (PODD)
2021 Conference

Boonton, NJ, October 26, 2021  — Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of […]
October 13, 2021

Enteris BioPharma to Participate in the American Association of Pharmaceutical Scientists (AAPS) 2021 PHARMSCI 360 Conference

Boonton, NJ, October 13, 2021  — Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of […]
September 29, 2021

Enteris BioPharma Announces Successful Completion of Phase 1 Clinical Trial of Optimized Peptelligence® Oral Leuprolide

Data indicates optimized Peptelligence® oral leuprolide formulation delivers comparable or greater drug levels than subcutaneous or depot injection   Boonton, NJ, September 29, 2021  — Enteris BioPharma, […]

KNOWLEDGE CENTER

Expand your knowledge. The Enteris BioPharma Knowledge Center is a library of educational tools.

LEARN MORE

KNOWLEDGE CENTER

Expand your knowledge. The Enteris BioPharma Knowledge Center is a library of educational tools.

LEARN MORE